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Abstract
Background: To evaluate the association between the clinical, dosimetric factors and severe acute radiation 
pneumonitis (SARP) in patients with locally advanced non-small cell lung cancer (LANSCLC) treated with concurrent 
chemotherapy and intensity-modulated radiotherapy (IMRT).
Methods: We analyzed 94 LANSCLC patients treated with concurrent chemotherapy and IMRT between May 2005 and 
September 2006. SARP was defined as greater than or equal 3 side effects and graded according to Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0.
The clinical and dosimetric factors were analyzed. Univariate and multivariate logistic regression analyses were
performed to evaluate the relationship between clinical, dosimetric factors and SARP.
Results: Median follow-up was 10.5 months (range 6.5-24). Of 94 patients, 11 (11.7%) developed SARP. Univariate 
analyses showed that the normal tissue complication probability (NTCP), mean lung dose (MLD), relative volumes of 
lung receiving more than a threshold dose of 5-60 Gy at increments of 5 Gy (V5-V60), chronic obstructive pulmonary 
disease (COPD) and Forced Expiratory Volume in the first second (FEV1) were associated with SARP (p < 0.05). In 
multivariate analysis, NTCP value (p = 0.001) and V10 (p = 0.015) were the most significant factors associated with SARP. 
The incidences of SARP in the group with NTCP > 4.2% and NTCP ≤4.2% were 43.5% and 1.4%, respectively (p < 0.01). 
The incidences of SARP in the group with V10 ≤50% and V10 >50% were 5.7% and 29.2%, respectively (p < 0.01).
Conclusions: NTCP value and V10 are the useful indicators for predicting SARP in NSCLC patients treated with 
concurrent chemotherapy and IMRT.
Background
Lung cancer is the leading cause of cancer-related death
in the urban areas of China, accounting for approximately
600,000 deaths per year [1]. Radiotherapy plays an impor-
tant role in the treatment of lung cancer, especially in
patients with unresectable tumors. Recent studies have
shown that concurrent chemoradiotherapy (CCRT) pro-
duced better survival rates than the sequential adminis-
tration of these two modalities [2-4]. Concurrent
chemoradiotherapy has become a standard method for
the management of unresectable locally advanced non-
small cell lung cancer (NSCLC). Unfortunately, the longer
survival is achieved at the price of greater toxicity of the
lung and the esophageal mucosa [3-5].
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Radiation pneumonitis is one of the most common
dose-limiting toxicities in lung cancer patients receiving
CCRT. Severe radiation pneumonitis is life-threatening
[5,6]. Many studies showed that dose and volume of radi-
ation to lung are associated with the risk of radiation
pneumonitis, such as mean lung dose (MLD) [7-11], nor-
mal tissue complication probability (NTCP) [8,12,13]
value and relative volume of lung receiving more than a
threshold dose (Vdose) [7,10,14-19]. Technology such as
intensity-modulated radiotherapy (IMRT) that could
reduce the dose and volume of radiation to lung would
potentially decrease the risk of severe radiation pneu-
monitis, as demonstrated in a planning study by Musherd
[20] et al. Further more, Yom et al reported that IMRT
was associated with a significantly reduced radiation
pneumonitis rate in NSCLC patients treated with concur-
rent chemotherapy and so far, this is the only study that
looked at concurrent chemotherapy and IMRT [21].
More clinical evidence on using IMRT in treating lung
cancer is needed.
W e started using IMRT to treat lung cancer in 2005,
and we evaluated clinical and dosimetric factors associ-
ated with severe acute radiation pneumonitis (SARP) in
94 patients with a diagnosis of locally advanced NSCLC
treated with concurrent chemotherapy and IMRT. The
results are reported here.
Methods
Patients
Between May 2005 and September 2006, 94 consecutive
locally advanced NSCLC patients were treated with con-
current chemotherapy and IMRT in the Department of
Radiation Oncology at the P eking University School of
Oncology, Beijing Cancer Hospital & Institute. Patients
were included if they had pathologically confirmed
NSCLC and clinically staged as IIIa or IIIb (AJCC 2002),
treated with concurrent chemoradiotherapy. Patients
were excluded if they received amifostine during concur-
rent chemotherapy and IMRT.
Treatment planning
Patients were positioned in the treatment position (gen-
erally supine with arms above their heads) and immobi-
lized by using a patient fixation device (Pelvicast Base
Plate, 35781-N1, Orfit industries) to improve the setup
reproducibility during CT simulation and delivery of
treatment. Treatment-planning CT scan was performed
using intravenous contrast if the patient was not allergic
to contrast agent. CT scans with slices 5 mm thick were
obtained from the mandible to the lower edge of the liver.
The CT image data were directly transferred to the IMRT
planning system (Varian Eclipse Treatment Planning Sys-
tems 7.0). Radiotherapy targets were defined according to
the International Commission on Radiation Units and
Measurements Report Nos. 50 and 62 [22,23], and the
internal target volume (ITV), which was used if the
required margin for target motion was visualized using
fluoroscopy, was defined as a three dimensional (3D)
expansion of the CTVprimary to account for target motion,
according to tumor motion. All patients' IMRT treatment
plans were designed on Varian Eclipse Treatment Plan-
ning Systems to deliver the prescribed dose (1.8-2.0 Gy
once per day, 60 Gy/30 fraction/6 weeks or 63 Gy/35 frac-
toin/7 weeks) to 95% of the planning target volume. Five
to seven fields were usually used in the treatment plan.
Heterogeneity correction with Eclipse-modified Batho
method was applied to all dose calculations. Lung dose-
volume histograms (DVH) were computed from the 3D
dose distributions. Dose limitation for OAR was defined
as follows: the V20 of lung less than 31%, the V55 of
esophagus less than 50%, the V40 of heart less than 40 Gy,
and the maximum dose administered to the spinal cord
was 40 Gy. The concurrent chemotherapy consisted of
two courses of Cisplatin-based chemotherapy regimen,
49 patients in all, and Paclitaxel regimen, 45 patients in
all.
Evaluation of SARP
Patients were generally evaluated by their radiation
oncologist weekly during concurrent chemoradiotherapy,
3-4 weeks after completion of treatment, every 3 months
in the first two years and 6 month intervals during years
three to five and once a year thereafter. Chest X-ray or
CT scan was performed at each follow-up after comple-
tion of chemoradiotherapy. If patients had symptoms,
such as fever, cough or shortness of breath, they would be
required to have an immediate examination or interven-
tion. A diagnosis of SARP was made with consensus by at
least two of three radiation oncologists and was based on
clinical symptoms and radiographic infiltrate changes
corresponding to the radiation portal observed during
concurrent chemoradiotherapy, within the first 6 months
after treatment and in the absence of any other likely
cause. SARP was defined as greater than or equal to grade
3 side effects (symptomatic, interfering with activities of
daily living, O2 indicated) and graded according to Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 3.0. [24].
Dosimetric parameters/NTCP models
The total normal lung volume was defined as the total
lung volume minus the primary GTV and volume of the
trachea and main bronchi. From each lung DVH, the fol-
lowing dosimetric factors were extracted: Vdose, MLD,
and NTCP, as derived from the Lyman and Kutcher mod-
els. The Vdose was defined as the percentage of total nor-
mal lung volume receiving more than a threshold dose D
of radiation (Vd), where values of D considered were 5-60Shi et al. Radiation Oncology 2010, 5:35
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Gy in increments of 5 Gy. The MLD was calculated as the
average dose to total normal lung volume [25]. For the
NTCP calculations, the Lyman empiric model was used
with the following parameters [9]: TD50 = 30.5 Gy, m =
0.3, and n = 1.
Statistical analysis
We evaluated clinical and dosimetric factors associated
with SARP in patients after concurrent chemoradiother-
apy. The following clinical parameters were considered:
gender, age, smoking and diabetes history, history of
COPD, induction chemotherapy, concurrent chemother-
apy regimens, performance status and forced expiratory
volume in 1 second (FEV1). Dosimetric factors including
MLD, V5-V60 and NTCP values were analysed. DVH
data and NTCP values were collected for both lungs con-
sidered as a parallel organ, Pearson Chi-Square test was
performed to compare clinical parameters between
patients who developed SARP and those who did not.
Univariate and multivariate logistic regression analyses
were performed to evaluate data for association between
clinical and dosimetric factors and SARP. All statistical
tests were 2-sided and p ≤ 0.05 was considered statisti-
cally significant.
Results
All patients were followed up more than 6 months. The
median follow-up for all patients was 10.5 months (range,
6.5-24.0 months). Of the 94 patients, 11 (11.7%) develop
SARP; 6 (6.4%), grade 3; 2(2.1%), grade 4; and 3 (3.2%)
grade 5. The SARP occurred between 4 week and 12 week
(median, 8 week) from commencement of radiation treat-
ment. There was no significant difference in the distribu-
tion of clinical parameters between the two groups of
patients who developed SARP and those who did not.
However, COPD and FEV1 were significant associated
with SARP (p < 0.05) (Table 1).
In univariate analysis, NTCP, MLD and V5-V60 were
associated with SARP (p < 0.05), and were summarized in
Table 2. In multivariate analysis, NTCP (p = 0.001) and
V10 (p = 0.015) were the most significant factors associ-
ated with SARP (Table 3). Table 4 shows the association
between the dosimetric Parameters (NTCP/V10) and the
incidence of SARP for 94 patients; the incidences of
SARP in the group with NTCP > 4.2% and NTCP ≤ 4.2%
were 43.5% and 1.4%, respectively (p  < 0.01); the inci-
dences of SARP in the group with V10 ≤50% and V10
>50% were 5.7% and 29.2%, respectively (p < 0.01).
Discussion
To the best of our knowledge, this is the first study to
evaluate clinical, dosimetric factors to predicate the risk
for developing SARP in locally advanced NSCLC patients
during or after concurrent chemotherapy and IMRT in
Chinese population. The univariate and multivariate
logistic regression analysis results suggest that NTCP and
V10 were the most significant factors associated with
SARP (p < 0.05).
Radiation pneumonitis takes place usually within 1-6
months after completion of radiation therapy [11], but it
can occur as late as 14 months after radiation in few
patients [19]. The clinical symptoms of radiation pneu-
monitis can lead to a poor quality of life for lung cancer
patients. Severe radiation pneumonitis after CCRT can
be life-threatening if patients are not responsive to treat-
ment. The reported incidences of radiation pneumonitis
were inconsistent because of inconsistencies in the crite-
ria used to define radiation pneumonitis, heterogeneity in
patient populations, and differences in treatment regi-
mens and radiotherapy techniques [7,11,15,19,26-28].
The incidence of SARP is 11.7% (11/94) in our study,
which was similar to that reported by Yom [21] with
IMRT, less than the other results with conventional or
conformal radiotherapy [15,19]. Perhaps this is because
we applied IMRT techniques, which had high conformity
and spared more normal lung from irradiation, and
therefore may have induced a low rate of severe radiation
pneumonitis. The diagnosis of radiation pneumonitis is
established by a history of radiotherapy, radiographic evi-
dence (ground-glass opacity, or consolidation changes
within the radiation field), and clinical symptoms (dry or
productive cough, fever, chest pain, and shortness of
breath). The treatment for radiation pneumonitis largely
includes oral or intravenous steroids, oxygen, antibiotics
and sometimes, assisted ventilation.
At present, there are no generally accepted means to
predict the individual patient's risk of developing radia-
tion pneumonitis morbidity accurately even though many
clinical and dosimetric assessment of radiation pneu-
monitis have been studied extensively [7-19]. However,
these studies lacked IMRT dosimetry data. In our study,
the patient population is quite homogeneous compared
with most published studies: 100% of the patients had
Stage III NSCLC, 100% of the patients are Han people,
and 100% received concurrent chemotherapy and IMRT.
The homogeneity of demographic data in the study
allowed us to focus on radiation dosimetric factors.
There are many reported studies [7,26,27,29-31] in
which the risks of radiation pneumonitis were found to
be associated with a variety of clinical parameters (see
Additional file 1). Sex, age, smoking history, pre-existing
pulmonary disease, performance score and pulmonary
function before radiotherapy have been reported to affect
the risk for radiation pneumonitis [7,26,29-31]. It also has
been reported [27,31] that chemotherapy, particularly
when combined with thoracic radiation therapy, was
associated with an increased risk for radiation pneumoni-
tis. However, (I) in our study, we only found that COPDShi et al. Radiation Oncology 2010, 5:35
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and FEV1 were significantly associated with SARP (p <
0.05), suggesting that the pulmonary function before
radiotherapy and base-line pulmonary disease is critical
for patients' well being after chemoradiotherapy. Our
findings are consistent with that of Robnett TJ [26] and
Rancati T [31]. The incidences of SARP in the group with
FEV1 > 2.02L and FEV1 < 2.02L were 7.04% and 26.09%,
respectively (p = 0.036). In addition, univariate analyses
show that there is not significant difference statistically
between the clinical parameters (sex, age, smoking and
diabetes history, induction chemotherapy, concurrent
chemotherapy regimens and PS) of patients with and
without SARP.
Several reports [7,9,11,14,15,19] showed that some
dosimetric factors are likely to influence the risk of radia-
tion pneumonitis (see Additional file 2), such as MLD,
NTCP and percentage volume of lung receiving more
than a threshold dose (Vdose). Hernando [7] reported
201 lung cancer patients treated with 3D conformal
radiotherapy, and the rate of radiation pneumonitis (all
grades) was significantly correlated with NTCP, MLD and
V30. Kwa [9] retrospectively analyzed 400 lung cancer
patients and found MLD was significantly correlated with
radiation pneumonitis (grades ≥ 2). Kim [11] reported a
study in which 76 lung cancer patients were treated with
3D conformal radiation therapy. In that study, the rate of
Table 1: Distribution of the clinical, treatment factors and their association with SARP for 94 patients
Characteristic No. of patients No. of RP(grade ≥ 3) p value*
Gender
Male 73 10 0.461
Female 21 1
Age
>60 53 8 0.401
≤60 41 3
smoking history
Yes 47 6 0.748
No 47 5
diabetes history
Yes 13 2 0.656
No 81 9
chronic obstructive 
pulmonary disease
Yes 11 4 0.027
No 83 7
induction chemotherapy
Yes 73 10 0.461
No 21 1
concurrent chemotherapy
NVB/DDP 28 3 0.643
TXT/DDP 21 2
PTX 45 6
Karnofsky performance status
≥70 80 7 0.093
<70 14 4
Fev1(L) **
≥2.02 71 5
<2.02 23 6 0.036
Abbreviation: * Comparison of clinical factors between patients who developed severe acute radiation pneumonitis and those who did not. 
** forced expiratory volume in 1 second. SARP = severe acute radiation pneumonitisShi et al. Radiation Oncology 2010, 5:35
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severe radiation pneumonitis (grades ≥ 3) was signifi-
cantly correlated with percentage of lung volume receiv-
ing 20 Gy (V20) or 30 Gy (V30), with NTCP and MLD.
SARP occurred in 45% and 37% of patients with MLD of
more than 15 Gy and NTCP of 50% or more, respectively,
whereas it occurred in 0% of patients with a MLD of 10
Gy or less and NTCP of less than 17%, respectively. In our
study, we found the NTCP and MLD were significantly
associated with the incidence of SARP. SARP occurred in
2.8% of patients in whom MLD was less than 14.1 Gy,
whereas it occurred in 40.9% of patients in whom MLD
was greater than 14.1 Gy. This is similarly to the other
study [7,9,11]. In addition, the V5-V60, in increments of 5
Gy, were all found to be significantly associated with the
incidence of SARP (see Additional file 2). These findings
are consistent with many other published results
reported by Wang et al. [19] (rV5-V65), Willner et al. [32]
(V10, V20, V30, and V40) or Fay et al. [33] (V30, V40, and
V50) to be significantly associated with the incidence of
radiation pneumonitis.
In our study, although the univariate analyses show that
NTCP, MLD, V5-V60, COPD and FEV1 were associated
with SARP (p < 0.05) however in multivariate analysis,
only NTCP (p = 0.001) and V10 (p = 0.015) were found to
be the significant factors associated with SARP statisti-
cally; the incidences of SARP in the group with NTCP >
4.2% and NTCP ≤ 4.2% were 43.5% and 1.4%, respectively
(p < 0.01). The incidences of SARP in the group with V10
≤ 50% and V10 >50% were 5.7% and 29.2%, respectively (p
< 0.01). While NTCP can predict the incidence of radia-
tion pneumonitis as confirmed by several studies [7,11], it
is inconvenient because of intricate mathematical calcu-
lations. However, in practice, V10 was easy to calculate
directly from the DVH, and furthermore, the V10 and
NTCP are highly correlated (rs = 0.930, p = 0.001). V10,
rather than V20, as an indicator suggests that radiation
damage to the lung during or after IMRT is correlated
with volume more closely than that of conventional or
conformal radiotherapy. This finding is coincident to
results reported recently by Wang et al [19], Zhu [34] and
Schallenkamp [35]. Wang et al reported that V5 was the
only significant factor associated with treatment-related
pneumonitis; the 1-year actuarial incidences of SARP in
the group with V5 <42% and V5 >42% were 3% and 38%,
respectively (p = 0.001). Schallenkamp suggested V10 and
V13 to be the predictors of radiation pneumonitis risk.
The incidences of Grade ≥ 2 pneumonitis in the patients
with V10 ≤ 32% 32%-43% and V10 > 43% were 0%-9%,
10%-20% and >20%, respectively (p < 0.01). This finding is
further confirmed by Yorke et al [10] and Gopal et al [36].
Table 2: Univariate analysis of the dosimetric parameters(MLD, NTCP, V5-V60) for predicting development of SARP for 94 
patients
Variable Median(range) No RP(n = 83) RP(n = 11) pvalue*
MLD 11.59(6.53-18.11) Gy  = 11.26, SD = 2.81  = 14.91, SD = 2.91 0.001
NTCP 2.33% (0.51-9.68%)  = 2.51, SD = 1.73  = 5.94, SD = 2.40 0.001
V5 58.73% (32.89-97.65%)  = 58.43, SD = 16.57  = 69.23, SD = 12.47 0.006
V10 42.16%(25.28-83.34%)  = 41.13, SD = 12.69  = 52.42, SD = 11.05 0.001
V15 29.53%(16.46-58.51%)  = 28.94, SD = 9.12  = 38.30, SD = 7.65 0.005
V20 18.15% (9.46-31.08%)  = 18.59, SD = 6.03  = 28.02, SD = 7.09 0.002
V25 12.96% (5.90-26.26%)  = 12.88, SD = 4.42  = 20.91, SD = 6.98 0.001
V30 10.00% (4.68-21.43%)  = 9.72, SD = 3.45  = 15.69, SD = 6.00 0.008
V35 9.92% (3.89-18.65%)  = 7.57, SD = 2.86  = 11.95, SD = 4.64 0.011
V40 8.20% (3.29-13.61%)  = 5.91, SD = 2.48  = 9.26, SD = 3.75 0.015
V45 7.42% (2.73-10.99%)  = 4.41, SD = 2.25  = 6.54, SD = 3.47 0.007
V50 7.07%(1.94-8.82%)  = 3.15, SD = 1.94  = 4.89, SD = 2.15 0.007
V55 6.75% (1.33-6.32%)  = 2.03, SD = 1.65  = 3.19, SD = 1.75 0.033
V60 5.76% (0.80-4.20%)  = 1.23, SD = 1.09  = 1.66, SD = 1.15 0.039
Abbreviation: MLD = mean lung dose; NTCP = normal tissue complication probability; SARP = severe acute radiation pneumonitis; * 
Comparison of dosimetric factors between patients who developed severe acute RP and those who did not
x x
x x
x x
x x
x x
x x
x x
x x
x x
x x
x x
x x
x x
x xShi et al. Radiation Oncology 2010, 5:35
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Yorke [10] reported that the incidence of radiation pneu-
monitis rose quickly when the MLD was higher than 10
Gy. Gopal et al [36] found a sharp loss in the diffusing
capacity for carbon monoxide of normal lung exposed to
13 Gy or higher, and suggested that a small dose of radia-
tion to a large volume of lung could be much worse than a
large dose to a small volume in functional lung damage.
So we think that the lung received a small dose of radia-
tion as low as 10 Gy to a large volume is not safe. In con-
t r a s t ,  W i l l n e r  [ 3 2 ]  e t  a l .  r e p o r t e d  t h a t  t h e  l o g i s t i c
regression curve for V10, V20, V30, and V40 showed an
increasing steepness toward higher doses and an increase
in steepness from V10 to V40 was more pronounced for
the total lung; A 10% increase in V10 resulted in a 10%
increase in pneumonitis rate, whereas a 10% increase in
V40 resulted in a 20% increase in pneumonitis rate. So
the investigators concluded that a small dose, such as 10
Gy, to a large volume of normal lung is preferable to a
large dose, such as 40 Gy, to a small volume. However, we
believe that the volume of normal lung receiving low-
dose irradiation should be minimized to avoid SARP. We
recommend to keep the value of V10 below 50%, so as to
keep the incidence of SARP lower than 5.7%.
In conclusion, NTCP and V10 are useful indicators of
risk for development of SARP in locally advanced NSCLC
patients after concurrent chemotherapy and IMRT. Tho-
racic concurrent chemoradiotherapy should be planned
with caution when the volume of normal lung receiving
10 Gy or more is large with IMRT.
Table 3: Multivariate analysis of the dosimetric and clinical factors associated with SARP for 94 patients
Varibale OR 95%CI p value*
NTCP 10.411 1.835-56.024 0.008
MLD 3.199 0.196-52.380 0.415
V5 4.024 0.765-21.163 0.100
V10 9.023 1.910-42.625 0.005
V15 4.024 0.765-21.163 0.100
V20 2.801 0.834-9.403 0.096
V25 3.423 0.713-16.421 0.124
V30 2.613 0.759-8.995 0.128
V35 2.313 0.751-7.122 0.144
V40 2.485 0.292-21.152 0.405
V45 1.219 0.373-14.146 0.475
V50 1.613 0.229-22.824 0.318
V55 1.446 0.215-20.061 0.594
V60 1.139 0.070-18.612 0.527
COPD 0.154 0.008-3.159 0.225
FEV1 0.119 0.010-1.346 0.085
Abbreviation: MLD = mean lung dose; NTCP = normal tissue complication probability; SARP = severe acute radiation pneumonitis; * Univariate 
logistic regression analysis; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; OR = the value of 
odds ratio; 95%CI = confidence interval
Table 4: Observed rates of SARP as a function of dosimetric parameters (NTCP/V10)
Varibale Median(Range) Group No. of patients No. of RP p value*
NTCP 2.33% ≤4.20% 71 1(1.4%) 0.001
(0.51-9.68%) >4.20% 23 10(43.5%)
V10 42.16% ≤50% 70 4(5.7%) 0.005
(9.91-83.34%) >50% 24 7(29.2%)
Abbreviation: NTCP = normal tissue complication probability; SARP = severe acute radiation pneumonitis; * Multivariate logistic regression 
analysis.Shi et al. Radiation Oncology 2010, 5:35
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